Harmony Biosciences Holdings (HRMY) Common Equity (2019 - 2026)

Harmony Biosciences Holdings has disclosed Common Equity across 8 years of filings, most recently posting $910.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $910.3 million, up 26.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $910.3 million (up 26.35% YoY), and the FY2025 annual result was $870.2 million, up 32.02% from the prior year.
• Common Equity came in at $910.3 million for Q1 2026 at Harmony Biosciences Holdings, up from $870.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $910.3 million in Q1 2026 to a low of $214.5 million in Q1 2022.
• The 5-year median for Common Equity is $515.4 million (2024), against an average of $559.0 million.
• Across the five-year window, Common Equity surged 126.21% in 2022 and increased 11.01% in 2024, its largest moves.
• Harmony Biosciences Holdings' Common Equity stood at $402.8 million in 2022, then increased by 15.93% to $467.0 million in 2023, then jumped by 41.15% to $659.2 million in 2024, then soared by 32.02% to $870.2 million in 2025, then increased by 4.61% to $910.3 million in 2026.
• The last three Common Equity figures came in at $910.3 million (Q1 2026), $870.2 million (Q4 2025), and $835.1 million (Q3 2025), per Business Quant data.